U.S. FDA Grants Accelerated Approval to Bayer’s Targeted Therapy Sevabertinib as a First-Line Treatment Option for Adults with HER2-Mutant Non-Small Cell Lung Cancer

Sep 10, 2026 - 09:00
 0  0
Berlin, September 9, 2026 – Following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug Administration (FDA) has granted accelerated approval for sevabertinib as a first-line treatment option for adult patients with...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0